Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

Bone Marrow Transplantation volume 28, pages 835–839 (2001)Cite this article

Abstract

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) has proved to be an effective salvage therapy for refractory-relapsed MM patients. Little is known, however, about its potential as mobilizing therapy. The aim of this study was to evaluate the efficacy of DCEP in mobilizing PBSC and to define its toxicity. Fifty-five MM patients received DCEP followed by G-CSF as part of high-dose programs including autologous transplantation. At the time of mobilization, 40 patients had previously received VAD only, and 15 alkylating agents. Mobilization was successful (minimum number of CD34+ cells 2 × 106/kg) in 48/55 patients (87%), and 41/55 patients (75%) collected >4 × 106/kg CD34+ cells. Of the seven patients who did not mobilize stem cells, five (71%) had been previously exposed to alkylating agents. The median number of CD34+ cells harvested was 5.8 × 106/kg (range 2.1–22.4). There was no treatment-related mortality. The side-effects of DCEP were always tolerable. No neutropenia <1000/μl nor thrombocytopenia <50 000/μl were observed. No patient required transfusion as a consequence of therapy, or hospitalization for septic complications. In conclusion, DCEP, in addition to its demonstrated anti-tumor activity, is an effective regimen for mobilizing peripheral blood progenitor cells in myeloma patients, with little or no side-effects. These properties render DCEP a useful regimen for the debulking and mobilization phase of high-dose programs for multiple myeloma. Bone Marrow Transplantation (2001) 28, 835–839.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Attal M, Harousseau J-L, Stoppa AM et al. Prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  3. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells J Clin Oncol 1995 13: 2547–2555

    Article  CAS  PubMed  Google Scholar 

  4. Scheid C, Draube A, Reiser M et al. Using at least 5 × 106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation Bone Marrow Transplant 1999 23: 1177–1181

    Article  CAS  PubMed  Google Scholar 

  5. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplant for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596

    CAS  PubMed  Google Scholar 

  6. Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma Bone Marrow Transplant 1996 17: 691–697

    CAS  PubMed  Google Scholar 

  7. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cells collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors Bone Marrow Transplant 1992 9: 11–17

    CAS  PubMed  Google Scholar 

  8. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of haemopoietic stem cells from the peripheral blood Exp Hematol 1990 18: 442–447

    CAS  PubMed  Google Scholar 

  9. Bensinger W, Buckner CD, Shannon DK et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy Blood 1996 88: 4132–4138

    CAS  PubMed  Google Scholar 

  10. Gorin NC, Lopez M, Laporte JP et al. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin lymphoma Blood 1995 85: 1647–1654

    CAS  PubMed  Google Scholar 

  11. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma Blood 1995 86: 390–397

    CAS  PubMed  Google Scholar 

  12. Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy Blood 2000 95: 2234–2239

    CAS  PubMed  Google Scholar 

  13. Stockerl-Goldstein KE, Brown JM, O'Brian RM et al. Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation using the Ceprate SC stem cell concentration system for multiple myeloma Blood 1999 94: (Suppl. 1) 2704a

    Google Scholar 

  14. Bensinger WI . Should we purge? Bone Marrow Transplant 1998 21: 113–115

    Article  CAS  PubMed  Google Scholar 

  15. Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophospamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens Bone Marrow Transplant 1999 23: 111–117

    Article  CAS  PubMed  Google Scholar 

  16. Cook G, Marinaki P, Farrell E et al. Peripheral blood progenitor cell mobilization in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy Leukemia 1997 11: (Suppl. 5) 35–40

    Google Scholar 

  17. Demirer T, Bukner CD, Storer B et al. The effect of different chemotherapy regimens on peripheral blood stem cell mobilization yield Proc Ann Meet Am Soc Oncol 1996 15: 1007a

    Google Scholar 

  18. Demirer T, Bukner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma Bone Marrow Transplant 1996 17: 937–941

    CAS  PubMed  Google Scholar 

  19. Desikan KR, Jagannath S, Siegel D et al. Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation Blood 1996 88: (Suppl. 1) 2331a

    Google Scholar 

  20. Munshi N, Desikan R, Anaissie E et al. Peripheral blood stem cell collection after CAD+ G-CSF as part of total therapy II in newly diagnosed multiple myeloma: influence of thalidomide administration Blood 1999 94: (Suppl. 1) 2577a

    Google Scholar 

  21. Desikan R, Munshi N, Zangari M et al. DCEP consolidation chemotherapy after 2 cycles of melphalan-based high-dose therapy. High incidence of CR and superior outcome in comparison with matched historical controls Blood 1999 94: (Suppl. 1) 1411a

    Google Scholar 

  22. Corso A, Caberlon S, Pagnucco G et al. Blood stem cell collection in multiple myeloma: definition of a scoring system Bone Marrow Transplant 2000 26: 283–286

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, IRCCS Policlinico S Matteo, University of Pavia, Italy

    M Lazzarino, A Corso & EP Alessandrino

  2. Division of Hematology, Ospedale Niguarda, Milano, Italy

    L Barbarano, R Cairoli & E Morra

  3. Division of Oncology, Varese, Italy

    G Pinotti

  4. Division of Oncology, Lecco, Italy

    G Ucci

  5. Division of Oncology, Milano S Paolo, Italy

    L Uziel

  6. Division of Hematology, Vicenza, Italy

    F Rodeghiero

  7. Division of Internal Medicine 2, Legnano, Italy

    S Fava

  8. Division of Internal Medicine, Abbiategrasso, Italy

    D Ferrari

  9. Division of Oncology, Sondrio, Italy

    M Fiumanò

  10. Division of Internal Medicine, Como, Valduce, Italy

    G Frigerio

  11. Division of Oncology, Gorgonzola, Italy

    L Isa

  12. Division of Oncology, Verbania, Italy

    A Luraschi & S Montanara

  13. Division of Hematology, Cremona, Italy

    S Morandi

  14. Division of Internal Medicine, Desio, Italy

    D Perego

  15. Division of Oncology, Vercelli, Italy

    A Santagostino

  16. Division of Internal Medicine, Magenta, Italy

    M Savarè

  17. Division of Internal Medicine 2, Rho, Italy

    A Vismara

Authors
  1. M Lazzarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Corso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Barbarano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. EP Alessandrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Cairoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Pinotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Ucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Uziel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Rodeghiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Fava
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Fiumanò
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Frigerio
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. L Isa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Luraschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Montanara
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S Morandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. D Perego
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A Santagostino
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. M Savarè
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. A Vismara
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. E Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lazzarino, M., Corso, A., Barbarano, L. et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 28, 835–839 (2001). https://doi.org/10.1038/sj.bmt.1703240

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703240

Keywords

This article is cited by

Search

Advanced search

Quick links